Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
10 déc. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
14 nov. 2024 07h00 HE
|
Nuvectis Pharma, Inc.
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:...
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
05 nov. 2024 07h00 HE
|
Nuvectis Pharma, Inc.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal...
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
23 oct. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
07 oct. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
29 août 2024 08h00 HE
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
06 août 2024 08h28 HE
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
16 mai 2024 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
07 mai 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the...